靶向METTL1/m7G轴作为髓系白血病的治疗策略
本研究探讨METTL1在白血病干细胞(LSC)稳态中的作用,发现METTL1通过催化tRNAPheGAA的m7G修饰促进白血病发生;抑制METTL1可降低LSC频率、延缓白血病进展并延长生存,提示其为可成药的表观转录组靶点。
要点
- METTL1通过tRNAPheGAA/m7G/HCK/CXCR4轴调控LSC自我更新与骨髓归巢。
- 小分子METTL1抑制剂M1i(NSC137443)在多个AML模型中显示抗白血病疗效。
- 靶向METTL1可减少LSC频率、延缓白血病发生并延长生存。
核心结论
- METTL1及其靶tRNAPheGAA在LSC稳态中起关键作用,METTL1是可成药的表观转录组抗白血病靶点。
研究设计与样本
- 本研究通过高通量筛选鉴定小分子METTL1抑制剂M1i(NSC137443),并在多个急性髓系白血病模型中验证其疗效。
主要发现
- METTL1缺失显著降低m7G丰度和tRNAPheGAA稳态水平,导致富含tRNAPheGAA相关密码子的转录本(如HCK)翻译抑制和降解。
- HCK表达下降破坏CXCR4信号,损害LSC自我更新和骨髓归巢。
- 药理抑制METTL1降低tRNA m7G水平并破坏tRNAPheGAA/HCK/CXCR4级联。
- 靶向METTL1显著降低LSC频率、延缓白血病发生并延长生存。
临床怎么用
- METTL1抑制剂M1i(NSC137443)可作为髓系白血病的潜在治疗策略,需进一步临床验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
N7-methylguanosine (m7G), a prevalent modification in transfer RNAs (tRNAs), is primarily catalyzed by the methyltransferase METTL1. Although growing evidence supports a role for METTL1 in various tumors, its therapeutic potential and precise function in leukemia stem cell (LSC) homeostasis remain largely unexplored. Here, we identify METTL1 as a key regulator of LSC self-renewal and homing within bone marrow (BM) microenvironment through catalyzing m7G formation on a specific tRNA, tRNAPheGAA, thereby promoting leukemogenesis. Mechanistically, METTL1 loss significantly reduces m7G abundance and steady-state levels of tRNAPheGAA, leading to translation suppression and degradation of transcripts enriched with tRNAPheGAA-related codons, such as hematopoietic cell kinase (HCK). Decreased HCK expression disrupts CXCR4 signaling, impairing LSC self-renewal and BM homing. Therapeutically, we characterized a small-molecule METTL1 inhibitor (M1i; NSC137443), through high-throughput screening. Pharmacological inhibition of METTL1 demonstrated potent antitumor efficacy by reducing tRNA m7G levels and disrupting the tRNAPheGAA/HCK/CXCR4 cascade. Notably, targeting METTL1 significantly reduces LSC frequency, delays leukemogenesis, and prolongs survival in multiple acute myeloid leukemia models. Together, our findings establish a previously unrecognized role for METTL1 and its target tRNAPheGAA in LSC homeostasis and provide compelling proof-of-concept evidence that METTL1 is a druggable epitranscriptomic target for antileukemia therapy.
引用
- Ren L, Zhang H, Bobileva O, et al. Targeting the METTL1/m7G axis as a therapeutic strategy in myeloid leukemia. Blood. 2026. PMID: 42247311. doi:10.1182/blood.2025030336
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。